Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12615001048572
ACTRN12615001048572
Not yet recruiting
Phase 4

Zoledronic acid to improve low bone mineral density in non-ambulatory adults with cerebral palsy

Anne Trinh0 sites40 target enrollmentOctober 7, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionscerebral palsyosteoporosisMusculoskeletal - OsteoporosisNeurological - Other neurological disorders

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
cerebral palsy
Sponsor
Anne Trinh
Enrollment
40
Status
Not yet recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 7, 2015
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Anne Trinh

Eligibility Criteria

Inclusion Criteria

  • •aged greater or equal to 18 years
  • •cerebral palsy
  • •non ambulatory (includes those who can stand for transfers only).
  • •Z score at lumbar spine or proximal femur less or equal to \-2\.0

Exclusion Criteria

  • •\-Secondary cause for bone disease (hypoparathyroidism, hyperparathyroidism, hypothyroidism, hyperthyroidism, rheumatoid arthritis, Paget’s disease
  • •\-Hypocalcaemia/hypercalcaemia
  • •\-Previous use of bisphosphonates in the last 2 years
  • •\-Current use of medication to treat osteoporosis: strontium, denosumab
  • •\-Use of glucocorticoids (washout period of 1 year)
  • •\-Calculated creatinine clearance of \<30ml/min as per Cockcroft Gault equation
  • •\-Pregnancy (F)
  • •\-Post\-menopausal (F)
  • •\-Current use of medications that can increase risk of renal dysfunction: diuretics, aminoglycosides

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate CancerProstatic NeoplasmsBone Density
NCT00489905Hospital Authority, Hong Kong24
Active, not recruiting
Phase 1
Zoledronic acid for prevention of bone loss after bariatric surgeryMorbid obese subjects undergoing bariatric surgeryTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2019-001650-26-DKHospital South West Jutland70
Unknown
Not Applicable
Effect of Zoledronic Acid on Prevention of Bone Loss in Acute Phase First-ever Stroke PatientsStroke
NCT04652128Yonsei University56
Active, not recruiting
Phase 1
Study to investigate changes in BMD of the lumbar spine (LS) one year after treatment discontinuation in denosumab-treated women and in denosumab-treated women who received a single infusion of zoledronic acid after treatment discontinuation.
EUCTR2016-000852-91-NLeiden University Medical Center75
Completed
Not Applicable
Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation: AfterDmabOsteoporosis
NL-OMON43199eids Universitair Medisch Centrum30